{
    "nctId": "NCT01019577",
    "briefTitle": "Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant",
    "officialTitle": "Phase II Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 54,
    "primaryOutcomeMeasure": "To assess the tumor response using RECIST Criteria to determine the best overall response and response rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women aged 20 years or older\n* Patients with metastatic breast cancer whose primary lesion was definitely diagnosed to be breast by histological or cellular examination\n\nExclusion Criteria:\n\n* Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of \u2265 2",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}